Targets › MECOM
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
[Isoform 1]: Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. (UniProt, Q03112)
Open in Phaseline: the race on MECOM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ciusss de L'Est de l'Île de Montréal | ECT-001-CB UM171-expanded umbilical cord blood stem cells | MECOM | Phase 1 | Acute Leukemia, High Risk | Oct 2027 |
Acute Leukemia, High Risk (1)
protein or peptide (1)
Ciusss de L'Est de l'Île de Montréal (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.